Showing results (291-300 of 301) with videos related to
Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphomaFranck Morschhauser, Françoise Kraeber-Bodéré, William A Wegener, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast CancerCaroline Rousseau, David M Goldenberg, Mathilde Colombié, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 30, 2012
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvementPierre-Yves Salaun, Loïc Campion, Claire Bournaud, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2017
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab GovitecanRebecca Suk Heist, Michael J Guarino, Gregory Masters, et al.The New England Journal of Medicine|February 21, 2019
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast CancerAditya Bardia, Ingrid A Mayer, Linda T Vahdat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Ingrid A Mayer, Jennifer R Diamond, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab GovitecanJhanelle E Gray, Rebecca S Heist, Alexander N Starodub, et al.The Lancet. Haematology|December 22, 2015
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation studyPatrice Chevallier, Thomas Eugene, Nelly Robillard, et al.The Lancet. Haematology|December 15, 2016
Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trialFrançoise Kraeber-Bodere, Amandine Pallardy, Hervé Maisonneuve, et al.The New England Journal of Medicine|April 21, 2021
Sacituzumab Govitecan in Metastatic Triple-Negative Breast CancerAditya Bardia, Sara A Hurvitz, Sara M Tolaney, et al.Pageof 31